Plus therapeutics announces topline results from recurrent glioblastoma external control analysis at asco 2023

Plus therapeutics' partnership with medidata resulted in a valid historical control arm for the company's phase 1/2 clinical and potential phase 3 trials evaluating rhenium ( 186 re) obisbemeda in recurrent glioblastoma (rgbm)

pstv Ratings Summary

pstv Quant Ranking